Head and Neck Cancers, Version 2.2013

Pfister, David G.; Ang, K. Kian; Brizel, David M.; Burtness, Barbara; Busse, Paul M.; Caudell, Jimmy J.; Cmelak, Anthony J.; Colevas, A. Dimitrios; Dunphy, Frank; Eisele, David W.; Gilbert, Jill; Gillison, Maura L.; Haddad, Robert I.; Haughey, Bruce H.; Hicks, Wesley L.; Hitchcock, Ying J.; Kies, Merrill S.; Lydiatt, William M.; Maghami, Ellie; Martins, Renato; McCaffrey, Thomas V.; Mittal, Bharat B.; Pinto, Harlan A.; Ridge, John A.; Samant, Sandeep; Schuller, David E.; Shah, Jatin P.; Spencer, Sharon A.; Weber, Randal S.; Wolf, Gregory T.; Worden, Frank; Yom, Sue S.; McMillian, Nicole R.; Hughes, Miranda

doi:10.6004/jnccn.2013.0113

Cited by 182 publications

(192 citation statements)

References 34 publications

Supporting

Mentioning

188

Contrasting

Unclassified

Order By: Relevance

“…This post-therapy evaluation to identify which patient will benefit from neck dissection is considered an indication by National Comprehensive Cancer Network and Society of Nuclear Medicine guidelines [40,41]. However, some data suggested no added value of PET compared with conventional imaging in this purpose, but these data were acquired on a PET-alone camera (not PET-CT) and performed as early as 7-weeks after completion of treatment [45].…”

Section: Challenges and Perspectives In Imaging Work-upmentioning

confidence: 99%

Advances in the management of squamous cell carcinoma of the head and neck

Machiels¹,

Lambrecht²,

Hanin³

et al. 2014

F1000Prime Rep

View full text Add to dashboard Cite

Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer worldwide. The main risk factors for cancers of the oral cavity, larynx, oropharynx, and hypopharynx are alcohol and tobacco use. In addition, the human papillomavirus (HPV) is an established cause of oropharyngeal cancer. An experienced multidisciplinary team is necessary for adequate management and optimal outcome. The treatment of locally advanced disease generally requires various combinations of radiotherapy, surgery, and systemic therapy, but despite this aggressive multimodal treatment, 40% to 60% of the patients will relapse. In this report, we will discuss recent advances in the management of SCCHN, including new developments in molecular biology, imaging, and treatment.

show abstract

Section: Challenges and Perspectives In Imaging Work-upmentioning

confidence: 99%

Advances in the management of squamous cell carcinoma of the head and neck

Machiels¹,

Lambrecht²,

Hanin³

et al. 2014

F1000Prime Rep

View full text Add to dashboard Cite

show abstract

“…At present, National Comprehensive Cancer Network (NCCN) guidelines for surveillance recommend history and physical examination at routine intervals with anatomic and metabolic imaging as clinically indicated (11). In contrast to malignancies of other anatomic sites for which biomarkers are integral to recurrent disease surveillance (e.g.…”

Section: Introductionmentioning

confidence: 99%

Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer

Fakhry

Qualliotine

Zhang

et al. 2016

Cancer Prevention Research

Self Cite

View full text Add to dashboard Cite

Human papillomavirus (HPV) is responsible for increasing incidence of oropharyngeal cancer (OPC). At present, there are no biomarkers in the surveillance algorithm for HPV-positive oropharyngeal cancer (HPV-OPC). HPV16 E6 antibody precedes OPC diagnosis. If HPV16 E6 indeed precedes primary diagnosis, it is similarly expected to precede disease recurrence and may have a potential role as a biomarker for surveillance of HPV-OPC. To determine whether HPV antibody titers have a potential role as early markers of disease recurrence or prognosis a retrospective pilot study was designed to determine whether HPV16 early antibody titers E6, E7, E1 and E2 decrease after treatment of HPV16-positive OPC. Trends in pre-treatment, early- (≤6 months after treatment) and late- post treatment (>6 months after treatment) HPV16 antibody titers were examined. There were 43, 34 and 52 subjects with serum samples available for pre-treatment, early- and late- post treatment intervals. Mean pre-treatment antibody levels were higher than post-treatment antibody levels. Average antibody levels decreased significantly over time for E6 (p-trend=0.001) and E7 (p-trend<0.001). 6 disease recurrences were observed during the follow-up period (median 4.4 years). In univariate analysis, a log unit increase in pre-treatment E6 titer was significantly associated with increased risk of disease recurrence (HR 5.42, 95%CI 1.1–25.7, p=0.03). Therefore, levels of antibodies to HPV16 early oncoproteins decline after therapy. Higher E6 titers at diagnosis are associated with significant increases in risk of recurrence. These data support the prospective evaluation of HPV16 antibodies as markers of surveillance and for risk stratification at diagnosis.

show abstract

“…Yine kılavuzda <2 cm hastalarda SLBB'nin daha etkin olduğu vurgulanmıştır (11). Baş boyun skuamoz hücreli kanserli hastalarda ise klinik olarak N0, T1 ve T2 tümörlerde SLBB önerilmektedir (12). Bahsettiğimiz pek çok kanser tipinde olduğu gibi vulvar ve penil karsinom gibi pek çok tümörde erken evre hastalarda SLBB kullanılmaktadır.…”

Section: Sentinellenfbezibiyopsisiunclassified

Sentinel Lymph Node Biopsy: Actual Approaches

Tuncel¹,

Salancı²,

Bozkurt³

2017

Nts

View full text Add to dashboard Cite

Öz Abstract GirişKanser yayılımında en önemli yollardan biri lenfatik yayılımdır. On yedinci yüzyılda lenfatik sistemin tanımlanması ve ardından kanserdeki rolünün saptanmaya başlaması ile bu konuda çeşitli çalışmalar yapılmıştır. Bu araştırmaların sonucunda bugün kanserin yerleştiği bölgeye bağlı olarak önce bölgesel lenf bezlerine ilerlediği ve klinik tanıdan çok daha önce bu bölgesel lenf bezlerinde mikrometastazların gerçekleştiği bilinmektedir. Bu bilgi özellikle meme kanseri ve malign melanom gibi kanserlerde sentinel lenf bezi (SLB) kavramının doğmasını sağlamıştır (1). İlk SLB tanımı Cabanas tarafından penil kanserde yapılmıştır (2). Lenfosintigrafinin SLB saptanmasında kullanılması Chiappa ve ark.'nın 1966'da testiküler kanserlerde yaptığı çalışma ile başlamıştır (3). Morton ve ark.'nın 194 malign melanom hastasında lenfosintigrafi kullanılarak lenfatik yayılımın araştırdığı çalışma SLB'nin örneklemesinin önünü açmış olup, günümüzde SLB sintigrafisi rutin uygulama kılavuzlarında yerini almıştır (4). Meme kanserlerinde de Christensen ve ark. ile başlayan çalışmalar koruyucu meme cerrahisi uygulamalarının yaygınlaşmasına ve hastaların daha az cerrahi komplikasyon ile tedavi edilmelerine olanak vermiştir (5). Son yıllarda gelişen görüntüleme ve intraoperatif deteksiyon teknolojileri sayesinde SLB biyopsisinin (SLBB) başarısı ve kullanım sıklığı

show abstract

Head and Neck Cancers, Version 2.2013

Cited by 182 publications

References 34 publications

Advances in the management of squamous cell carcinoma of the head and neck

Advances in the management of squamous cell carcinoma of the head and neck

Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer

Sentinel Lymph Node Biopsy: Actual Approaches

Contact Info

Product

Resources

About